During Monday’s Current trade, Shares of Denbury Resources Inc. (NYSE:DNR), lost -2.42% to $2.82.
Denbury Resources Inc. (DNR) stated, as required by the New York Stock Exchange (the “NYSE”), an equity inducement award to Chris Kendall, the Company’s new Chief Operating Officer, who officially joined the Company recently.
As an inducement for employment, the Compensation Committee of the Board of Directors of the Company granted Mr. Kendall a one-time award of 300,000 shares of restricted common stock of the Company on September 8, 2015 (the “Inducement Award”). This grant was made outside of the Company’s current equity plan, but will be subject to terms and conditions generally compriseent with those in the Company’s Amended and Restated 2004 Omnibus Stock and Incentive Plan. The Inducement Award will vest ratably over a three-year period, or upon an earlier change-of-control of the Company or upon Mr. Kendall’s death or disability, subject to forfeiture of unvested portions of the Inducement Award upon separation from the Company in certain circumstances, as more fully described in the award agreement to be filed as an exhibit to the Current Report on Form 8-K on September 8, 2015 with the Securities and Exchange Commission.
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region. As of December 31, 2014, it had 437.7 million barrels of oil equivalent of estimated proved oil and natural gas reserves.
Shares of Seattle Genetics, Inc. (NASDAQ:SGEN), inclined 0.56% to $45.27, during its current trading session.
Seattle Genetics, Inc. ( SGEN) declared that the underwriters of its formerly declared public offering of common stock have exercised in full their over-allotment option to purchase an additional 1,756,097 shares of common stock. Counting this option exercise, total gross proceeds from the offering of an aggregate of 13,463,415 shares at a price to the public of $41.00 per share will be about $552 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is predictable to close on September 16, 2015, subject to customary closing conditions.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially accessible in about 55 countries, counting the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in partnershipwith Takeda Pharmaceutical Company Limited.
Interpublic Group of Companies Inc (NYSE:IPG), during its Monday’s current trading session gained 0.20% to $19.70.
Interpublic Group (IPG) senior administration will present at the Goldman Sachs 24th Annual Communacopia Conference on Thursday, September 17th, 2015, at 8:50 am Eastern time, as planned.
The Interpublic Group of Companies, Inc. provides advertising and marketing services. The company operates in two segments, Integrated Agency Netoperates and Constituency Administration Group. It offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines. The company also offers various diversified services, counting public relations, meeting and event production, sports and entertainment marketing, corporate and brand identity, and planned marketing consulting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
